Collaborations
Bristol-Myers Squibb, AstraZeneca to develop, commercialize diabetes compounds
Published in Obesity and Diabetes Week, February 5th, 2007
Both compounds were discovered by Bristol-Myers Squibb.
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently in phase III development. Upon successful completion of the development program, the companies plan to file for U.S. regulatory approval of saxagliptin during the first half of 2008. Dapagliflozin (previously referred to as BMS-512148), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is currently in phase IIb development. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity Research
Study shows a new fat replacement for trans fat raises blood sugar in humans - Obesity and Diabetes
Data on obesity and diabetes in children described by researchers at Instituto Nacional de Perinatologia - Obesity and Diabetes
Data on obesity and diabetes in children reported by researchers at Sungkyunkwan University - Obesity and Diabetes
New findings from Natura, Department of Biological Science in the area of obesity and diabetes described - Obesity and Diabetes
New obesity and diabetes data have been reported by scientists at National Cheng-Kung University, Department of Physical Therapy - Obesity and Diabetes
New obesity and diabetes data have been reported by scientists at University of Texas, Health Science Center - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
